ADA 2026 Scientific Sessions: The GLP-1 Data That Matters

Every June, the American Diabetes Association's Scientific Sessions is where the next few years of obesity and diabetes care quietly get decided. The 86th edition wrapped up in New Orleans the weekend of June 5–8, and the headline is no longer a single blockbuster drug — it is choice. More molecules, more delivery formats, and more direct comparisons than the GLP-1 era has ever seen at once. Here is what landed, in plain language, and what it means if you are already on this journey.

TL;DR ADA 2026 confirmed retatrutide as the most powerful weight-loss drug yet studied (about 28% at 80 weeks) — but it is still investigational and roughly 1 in 9 people on the top dose stopped for side effects. The bigger story is breadth: an approved oral GLP-1 (Foundayo) that beat oral semaglutide, plus three more contenders moving up. The medication is widening. The work underneath it has not changed.

Key Takeaways

Retatrutide hit ~28.3% average weight loss (about 70.3 lbs) at 80 weeks on the highest dose in the TRIUMPH-1 trial — the largest figure for any obesity drug to date — but it remains investigational and only available in clinical trials [1][2].
Foundayo (orforglipron), the first oral GLP-1 you can take any time without food or water restrictions, beat oral semaglutide in a head-to-head, with 73.6% greater relative weight loss at 52 weeks [1].
The field is crowding fast — Boehringer's survodutide, Sciwind's ecnoglutide, and AstraZeneca's oral elecoglipron all posted gains [2][3].
Tolerability is the recurring asterisk. Across the strongest results, gastrointestinal side effects and discontinuations rose with potency [2].
Approval is not availability, and availability is not "right for you." New options change the menu, not the daily work.

Retatrutide: the biggest number yet — and the asterisk

Lilly's retatrutide is a "triple-G" agonist — it acts on GIP, GLP-1, and glucagon receptors at once. In the pivotal TRIUMPH-1 trial (NCT05929066), adults with obesity on the 12 mg dose lost an average of 28.3% of their body weight — about 70.3 lbs — at 80 weeks, and roughly one-third reached a BMI of 25 or lower [1][2]. It also moved the things that ride along with weight: knee osteoarthritis pain fell by 4.3 points, and sleep-apnea breathing events dropped 60.6% (from 58.6 to 36.1 per hour) [2]. In the separate TRANSCEND-T2D-1 study, it lowered A1C by up to 2.0% and weight by 16.8% in type 2 diabetes [1].

The asterisk is tolerability. On that same 12 mg arm, 11.3% of people discontinued because of side effects, and 25.3% reported vomiting [2]. And the most important caveat for anyone tempted by the headline: retatrutide is investigational. It is not FDA-approved and is legally available only inside Lilly's trials [1]. We unpacked the full TRIUMPH-1 picture — including who the trial studied — in our retatrutide Phase 3 breakdown.

Foundayo: the oral GLP-1 grows up

If retatrutide was the spectacle, Foundayo (orforglipron) was the practical news. It is a once-daily pill — a small-molecule GLP-1 you can take any time of day, with or without food or water [1]. At ADA, the Phase 3 ACHIEVE program showed Foundayo was superior to oral semaglutide, delivering better blood-sugar control and 73.6% greater relative weight loss at 52 weeks [1]. Against dapagliflozin it lowered A1C by 1.7% versus 0.8% [1]. A subgroup analysis also found more than 14% weight reduction in women who were peri- or post-menopausal — a group historically underserved by weight research [1].

Why this matters: a needle-free, food-flexible option lowers two of the quieter barriers to starting and staying on treatment. If you are weighing a pill against an injection, our oral GLP-1 decision guide walks through the trade-offs.

The field is crowding fast

Three more names showed up with real data:

Survodutide (Boehringer Ingelheim / Zealand Pharma), a glucagon/GLP-1 injectable, has shown 16.6% weight loss at 76 weeks versus 3.2% on placebo, with most of that loss coming from fat rather than lean tissue, and strong liver-fat results [2]. Analysts expect it to be the third peptide incretin approved for obesity — though gastrointestinal discontinuations ran 19% versus 2.9% on placebo [2].
Ecnoglutide (Sciwind Biosciences), in a Phase 2 head-to-head in China, produced 35% greater body-weight reduction than Wegovy over 20 weeks [2]. Encouraging, but short and early.
Elecoglipron (AstraZeneca), another oral GLP-1, posted 10.5% weight loss with better blood sugar in a Phase 2b trial reported this week [3].

The pattern is clear: the era of one or two options is ending. The era of choosing between several is beginning.

What this actually means for you

It is genuinely good news that the menu is widening — more formats, more price pressure over time, more ways to find a fit. But a conference headline is not a prescription. Three honest reminders:

Investigational ≠ available. Retatrutide, survodutide, ecnoglutide, and elecoglipron are not approved options you can ask for today. Foundayo is approved; the rest are still in trials [1][2].
Bigger numbers come with bigger asterisks. The strongest results carried the highest side-effect and discontinuation rates [2]. The "best" drug is the one you can actually stay on.
The molecule is the floor, not the finish. Whatever you take, the durable part of this — protecting muscle, eating in a way you can sustain, navigating the return of food noise if you ever stop — is the same. That is the part Gila is built to help you keep. A practical place to start is our guide to what to eat on a GLP-1, and if you are still deciding whether treatment fits your situation, the GLP-1 eligibility checker is a quiet first step.

This article covers research presented at a medical conference. It is not medical advice. Many of the medicines discussed are investigational and not FDA-approved. For questions about your own treatment, talk to your prescriber.